A Study to Determine Baseline Levels for Prostate Cancer-Derived Particles Containing Cellular Matter (Extracellular Vesicles) After Local Treatment

Overview

About this study

The purposes of this study are to determine the levels of prostate cancer-derived extracellular vesicles pre- and post-local therapy (radical prostatectomy or radiation therapy), to correlate analysis for PSA levels and prostate cancer-derived extracellular vesicles, and to determine baseline levels of prostate cancer-derived extracellular vesicles in patients undergoing different lines of primary local treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18+ years of age.
  • Able to give informed consent.

Prostate Cancer Patients

  • Patients with intermediate-risk, high-risk or very-high risk prostate cancer (≥ Grade Group 2).
  • Patients scheduled to undergo open radical prostatectomy (ORP).
  • Patients scheduled to undergo conventional laparoscopic radical prostatectomy (LRP).
  • Patients scheduled to undergo robot-assisted laparoscopic radical prostatectomy (RALP).
  • Patients scheduled to undergo external beam radiation therapy (EBRT).

Nephrolithiasis Patients

  • Patients treated for nephrolithiasis (Extracorporeal Shock Wave Lithotripsy/Surgery).    

Exclusion Criteria:                                 

Prostate Cancer patients

  • Unable or unwilling to provide informed consent.
  • On hormone therapy (Casodex, GnRH agonist/antagonist).
  • Patients with Benign Prostatic Hyperplasia (BPH).
  • Active (non-skin) malignancy within the past 5 years excluding prostate cancer.

Nephrolithiasis Patients

  • Unable or unwilling to provide informed consent.
  • History of Benign Prostatic Hypertrophy (BPH).
  • Active (non-skin) malignancy within the past 5 years including prostate cancer.

Eligibility last updated 3/2/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Eugene Kwon, M.D.

Open for enrollment

Contact information:

Mikayla Schmidt

(507) 422-5768

schmidt.mikayla2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20502007

Mayo Clinic Footer